“p53 Polymorphism at Codon 72 and Breast Cancer” - Letter

Article information

J Cancer Prev. 2017;22(1):55-55
Publication date ( electronic ) : 2017 March 30
doi : https://doi.org/10.15430/JCP.2017.22.1.55
1Department of Modern Sciences and Technology, Mashhad University of Medical Sciences, Mashhad, Iran
2Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3Division of Applied Medicine, Medical School, University of Aberdeen, Aberdeen, UK
Correspondence to: Alireza Pasdar, Department of Modern Sciences and Technology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, Tel: +98-5138002310, E-mail: pasdara@mums.ac.ir
received : 2017 February 07, accepted : 2017 February 15.

Dear Editor:

We read with interest the recently published systematic review and meta-analysis titled “The Evaluation of p53 Polymorphism at Codon 72 and Association With Breast Cancer in Iran: A Systematic Review and Meta-analysis”.1 We believe that there are few important issues in the systematic review and meta-analysis that require clarification. A key characteristic of a systematic review is a comprehensive search to find eligible studies. This study has been conducted between 2007 and 2014, however, one study has been missed.2 According to the date of publication, a study published in 2015 has also been missed.3 Furthermore, Hardy–Weinberg equilibrium (HWE) test is commonly used for quality control of genotyping and is one of the few ways to identify systematic genotyping errors.4 It seems that authors have not considered testing HWE for quality assessment of the included studies. Once we checked, the reported pooled data did not follow the HWE. Therefore, because of the lack of HWE analysis, the interpretation of these results may be difficult.

The appropriate sample size is a major issue in genetic case-control studies analyzing the association of polymorphisms with disease susceptibility. It seems the authors have also missed commenting on the statistical power in this study.

The random-effect method assumingly was used to measure association because of heterogeneity, but identifying the source of the heterogeneity could also be helpful to figure out the properties of those particular studies. Overall, we urge mentioning the missing data and also lack of quality control for the included studies to strengthen the conclusion reached by the authors.



No potential conflicts of interest were disclosed.


1. Soleimani A, Rahmani Y, Farshchian N, Delpisheh A, Khassi K, Shahmohammadi A, et al. The evaluation of p53 polymorphism at codon 72 and association with breast cancer in Iran: a systematic review and meta-analysis. J Cancer Prev 2016;21:288–93.
2. Saadatian Z, Gharesouran J, Ghojazadeh M, Ghohari-Lasaki S, Tarkesh-Esfahani N, Mohaddes Ardebili SM. Association of rs1219648 in FGFR2 and rs1042522 in TP53 with premenopausal breast cancer in an Iranian Azeri population. Asian Pac J Cancer Prev 2014;15:7955–8.
3. Gohari-Lasaki S, Gharesouran J, Ghojazadeh M, Montazeri V, Mohaddes Ardebili SM. Lack of influence of TP53 Arg72Pro and 16bp duplication polymorphisms on risk of breast cancer in Iran. Asian Pac J Cancer Prev 2015;16:2971–4.
4. Wittke-Thompson JK, Pluzhnikov A, Cox NJ. Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 2005;76:967–86.

Article information Continued

Related article (letter) :